å»è¬åå ¬è¡šãããæŽå¯
æ ¢æ§ã®Idiopathicã®äŸ¿ç§(CIC)ã®åŠçœ®ã®åžå Žã®ãµã€ãº äºæž¬ â 2026 â 2033äžçã®æ ¢æ§ã® Idiopathic ã®äŸ¿ç§ã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯ãããŸã 2026幎ã®USD 3.8åã§è©äŸ¡ããããšäºæ³ããã ååç©ã®å¹Žéæé·çã瀺ã2033幎ãŸã§ã®USD 6.5åã«éãã 2026ã2033幎(CAGR)ãããã£ãŒã«æ ¢æ§Idiopathicã®äŸ¿ç§(CIC)ã®åŠçœ®ã®åžå Žã¯é転ãããŸã ã«ãªã³ã¯ãããŠããæ¶å管ã®é害ã®äžæã®å šäœçãªåªå é äœã«ãã£ãŠ å¿èº«ã®ã©ã€ãã¹ã¿ã€ã«ãè²§ããé£ç¿æ £ãã¹ãã¬ã¹ã¬ãã«ã®å¢å ã æ¶ååšã®å¥åº·ã®æèãé«ãããã«ã¹ã±ã¢ãžã®ã¢ã¯ã»ã¹ãæ¡å€§ 蚺æãšæ²»çãæ±ãã... ãã£ãšèŠã
ãŸããªç æ°ãå€å ã®ç æ°ã¯ãä»»æã®æç¹ã§ã®äººå£ã®ããããªå²åã«åœ±é¿ãäžããæ¡ä»¶ã§ãã Orphanã®è¬å€ ãŸããªç æ°ã®æ²»çã®ããã«ç€ºãããŠããè¬ã«æå®ãäžããããŸãã ç±³åœé£åå»è¬åå±(FDA)ã«ãããšããªãŒãã¡ã³ç ã¯ãåœã®20äžäººæªæºã®äººã ã«åœ±é¿ãåãŒãçŸæ£ãŸãã¯æ¡ä»¶ãšããŠå®çŸ©ãããŠããŸãã Orphanã®è¬å€ ç±³åœæ³ã«åºã¥ãè¡çºã¯è£œé æ¥è ããŸããªç æ°ãæ¡ä»¶ãæ±ãããšãæå³ããè¬å€ã«Orphanã®è¬å€ã®ç¶æ ãä»äžããããã«FDAãèŠæ±ããããšãå¯èœã«ããŸãã FDAã«ãããšã2017幎ããªã«ãã¡ã³ã®è¬ç©æå®ã®èŠæ±ã®æ°ã¯é廿°å¹Žéã«çå®ã«å¢å ããŸãããäžççãªãŸããªç æ°ã®è¬ã®åžå Žã¯æè¿ãŸã§æå©ãš... ãã£ãšèŠã
äžçã®åç©ã®æ®ºè«å€ åžå ŽèŠæš¡ã¯è©äŸ¡ããããšæšå®ããã US$ 10.8 ã§ 2023 ãããŠå°éããäºå® US$ 16.4 ã«ãã£ãŠ 2030, å±ç€º 2023幎ãã2030幎ãŸã§ã®6.1%ã®ååç©å¹Žéæé·ç(CAGR)ãåãåãã åç©å¯çè«é§é€å€ åžå Žã§ã®æé·ã¯ãåç©ã®ç æ°ã®å¢å ã®èå»¶ãå®¶çåç©ã®äžæäººå£ã®å¢å ãèã乳補åã«å¯ŸããéèŠã®å¢å ãªã©ã®èŠå ã«ãããã®ã§ããã°ããŒãã«åç©æ®ºè«å€åžå Žå°åæŽå¯åã¢ã¡ãªã« åç©çšæ®ºè«å€ã¯ããã®å€§ããªå®¶çã®äººå£ãããã³å°åã®ç¢ºç«ãããåç©å¥åº·ç£æ¥ã®ååšã«ããåžå Žãæ¯é ããŸãã åç±³ã¯44.3%ã®åžå Žã·ã§ã¢ãæã£ãŠããŸãã ç±³åœèŸ²æ¥ç(USDA)ã®ããŒã¿ã«ã... ãã£ãšèŠã
ã«ã«ã·ãŠã ãµããªã¡ã³ãåžå Žã補åã¿ã€ãå¥ïŒçé žã«ã«ã·ãŠã ãã¯ãšã³é žã«ã«ã·ãŠã ããã®ä»ïŒã圢æ å¥ïŒé å€ãã«ãã»ã«ããã³ãœãããžã§ã«ãç²æ«ããã³æ¶²äœïŒããšã³ããŠãŒã¶ãŒå¥ïŒæäººãé«éœ¢è 人å£ãåäŸããã³éå°å¹ŽïŒãæµéãã£ãã«å¥ïŒè¬å±ããã³ãã©ãã°ã¹ãã¢ãã¹ãŒããŒããŒã±ããããã³å€§åãã€ããŒããŒã±ãããããã³ãªã³ã©ã€ã³å°å£²ïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³èªïŒ ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«ïŒ... ãã£ãšèŠã
ã¯ã©ãã©ã³é žã«ãªãŠã åžå Žã補å€ã¿ã€ãå¥ïŒçµå£è£œå€ããã³æ³šå°è£œå€ïŒãçšéå¥ïŒæ°éææçãå°¿è·¯ææçãç®èããã³è»éšçµç¹ææçããã®ä»ã®çŽ°èææçïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ã蚺çæãåšå® å»çæœèšãªã©ïŒãæµéãã£ãã«å¥ïŒç é¢è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³ïŒ è¬å±)ãå°çå¥ (åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
ã«ã«ã·ãŠã ããããã·ã©ããããã¯é¡ã®æç®ã®ãããªæ¡ä»¶ã§è€æ°ã®ç®èç§ã®å¡åžã§äœ¿çšãããåºã䜿çšãããç®èåæ°žä¹ çãªããã®æ³šå ¥å£ããã³è£å ã«ãã£ãŠå€±ãããé¡ã®å®¹ç©ã§ãã Calcium ããããã·ã©ããããã¯ãé¡ã®è»éšçµç¹ã®å¢æ®ã«äœ¿çšããéåè¬ã§ãã ã«ã«ã·ãŠã ããããã·ã©ããã©ã€ãã¯é«ãå®å šãããã£ãŒã«ã«é¢é£ä»ããããé·æã³ã©ãŒã²ã³ã®åœ¢æã«å°ãé«ã䌞瞮æ§ããã³ç²çæ§ããããŸãã ã«ã«ã·ãŠã ããããã·ã©ããã©ã€ãã¯ç²åºŠãåŒŸåæ§ãåéæ§ãªã©ã®ç©ççç¹æ§ãæã£ãŠããŸãã Calciumããããã·ã©ããããã¯ããã©ã³ãããããã€ã¯ãã«ãã©ã§éèçã«æäžãããŸããGlobal ã«ã«ã·ãŠã ããããã·ã¢ãã¿ã€... ãã£ãšèŠã
ã¢ã»ã¿ãŸã©ããã¯çé žè±æ°Žé µçŽ é»å®³è¬ã§ãæ ¢æ§åçŽïŒéæŸïŒç·å éãç¶çºæ§ç·å éã®è£å©çæ³ãæ¥æ§éå¡é è§ç·å éã®è¡åæ²»çããŠãããããã£è¡æ§å¿äžå šã«ããæµ®è «ãè¬ç©èªçºæ§æµ®è «ãç»å±±å®¶ã®æ¥æ§é«å±±ç ã«çšãããããã¢ã»ã¿ãŸã©ããã¯é«åºŠé å¿ãä¿é²ããè èããã®éçé žå¡©åæ³ãå¢å ãããä»£è¬æ§ã¢ã·ããŒã·ã¹ãèªçºããææ°ãä¿é²ãããããã«ã2012幎9æã®BMJãžã£ãŒãã«ã«ãããšãã¢ã»ã¿ãŸã©ããã¯1æ¥250mgã500mgã750mgã®çšéã§ããã©ã»ããšæ¯èŒããŠæ¥æ§é«å±±ç ã®äºé²å¹æãé«ãããŸããã¢ã»ã¿ãŸã©ãã1æ¥250mgã¯ãæ¥æ§é«å±±ç ã®äºé²ã«æã广çãªçšéã§ããã ã¢ã»ã¿ãŸã©ããã®äžçåžå ŽèŠæš¡ã¯2017幎ã«1... ãã£ãšèŠã
ã¬ã¹ãã©ãããŒã«åžå Ž - æŽå¯ ã¬ã¹ãã©ãããŒã«ã¯ããã©ããã€ãã®ã°ã«ãŒãã«å±ãããã©ãããŒã«ã§ãããã¬ã¹ãã©ãããŒã«ã¯ãæ§ã ãªæ€ç©ã现èãçèãªã©ã®ç åèã«äŸµããããšãã«èªç¶ã«åæããããã¡ã€ãã¢ã¬ãã·ã³ã§ãããã¬ã¹ãã©ãããŒã«ã¯ãèµ€ãããŠãããŒãããããã«ãŒããªãŒãæ¡ã®å®ãã©ãºããªãŒããŠãŒã«ãªãããŠããªã©ãããŸããŸãªæ€ç©ãæå®ã«å«ãŸããŠãããã¬ã¹ãã©ãããŒã«ã¯ãå»è¬åãåç²§åãæ é€è£å©é£åã«åºãå©çšãããŠããã ã¬ã¹ãã©ãããŒã«ã¯ããããå¿è¡ç®¡ç³»çŸæ£ãç³å°¿ç ãç¥çµç³»çŸæ£ãªã©ã®æ§ã ãªçŸæ£ãæ²»çã»ç®¡çããç¹æ§ãæã£ãŠãããããè£œè¬æ¥çã§åºãå¿çšãããŠãããåç²§åæ¥çãæ é€è£å©é£åæ¥çã§ã¯ã... ãã£ãšèŠã
Diclofenacã¯åžå ŽèŠæš¡ãšäºæž¬ãããã â 2026 â 2033幎ã°ããŒãã«Diclofenacãããåžå ŽèŠæš¡ã¯è©äŸ¡ããããšæšå®ãããŸã 2026幎ã®USD 1.1åã§ãUSD 1.9åã«éããèŠèŸŒã¿ 2033幎ã2026幎ãã8.1%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º 2033幎é ãããã£ãŒã«Diclofenacã®ãããã¯ãšåœ¢æããã話é¡ã®çã¿ã®è»œæžãããã¯ãã§ã éã¹ããã€ãã®ççæå¶ã®è¬å€(NSAID)ã®diclofenacãèšèšããŸãã 屿çãªçã¿ãççãããã³musculoskeletalæ¡ä»¶ãæ±ãã ãããã®ãããã¯ç®ãéããŠå¶åŸ¡ãããè¬å€ã®è§£æŸãæäŸããŸããæžããŸã ... ãã£ãšèŠã
Betaxolåžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033ã°ããŒãã«ã»ãã¿ããœãŒã« åžå ŽèŠæš¡ã¯ç±³ãã«1.8ã§è©äŸ¡ããããšæšå®ããã 2026 åç±³ãã«ã2033 åç±³ãã«ã«éããèŠèŸŒã¿ 2026幎ïœ2026幎ã«ãããŠ8.1%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± 2033幎ããããã£ãŒã«Betaxol ã®åžå Žã®äž»èŠãªé転è ã¯å¢å ã® prevalence ãå«ãã§ããŸã ã°ã©ãŠã³ãããã³æ¥åé«è¡å§ãèåã®äžççãªäººå£ã«ãã£ãŠé転ããã ã¹ã¯ãªãŒã³é¢é£ã®ç®ã®ç·åŒµãå¢å ããã æé·ã®çºçç é«è¡å§ã®ãããªå¿è¡ç®¡ã®ç¶æ ã¯æŽã«å šèº«ãæ¯ããŸã ããŒã¿ãããã«ãŒã®èŠæ±ã çŒç§ã±ã¢ãžã®ã¢ã¯ã»ã¹ãæ¡å€§ ãã倧ãã蚺... ãã£ãšèŠã
Erythromycin åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎ã°ããŒãã«ã»ãšãªã¹ããã€ã·ã³ åžå ŽèŠæš¡ã¯ç±³ãã«ã§è©äŸ¡ããããšæšå®ããã 2026幎ã«1å15åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2033幎ãŸã§ã«1.87åç±³ãã«ã«éããèŠèŸŒã¿ 2026幎ãã6.5%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± 2033幎ããããã£ãŒã«erythromycinã®åžå Žã¯äžæã®åªå é äœã«ãã£ãŠé転ãããŸã 现èã®äŒæãç¹ã«åŒåžç®¡ã®ãç®ããã³æ§çã« æå¹ãªãã¯ãã©ã€ããèŠæ±ãç¶ããéä¿¡ãããäŒæ æçç©è³ªã æçç©è³ªã®æµæã®å¢å ããµããŒãããŸãã ãšãªã¹ããã€ã·ã³ãæ®ã£ãŠãã代æ¿ãŸãã¯çµã¿åããçæ³ã®å¿ èŠæ§ é¢é£ãã... ãã£ãšèŠã
æªæ§ã¢ã·ãããæ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎äžçã®æªæ§Ascitesã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯ã§ãããšæšå®ãããŸã 2026幎ã«1åç±³ãã«ã«çžåœããUSD 2.75ã«éããèŠèŸŒã¿ 2033幎(æå20幎)ã9.6%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º 2026幎ïœ2033幎ãããã£ãŒã«æªæ§Ascitesã®åŠçœ®ã®åžå Žã¯äžæã«ãã£ãŠé転ãããŸã åµå·£ãèèãèãããã³èµèãªã©ã®çã®èå»¶ ç, äžè¬çã«è ¹éšã®æµäœèç©ã«ã€ãªããã æ¡çšæ å ± å é²çã«ããäžççãªããã®è² æ ãšé·æã«ãããæ£è ã®çå è «çåŠçæ³ã¯ãæªæ§ã®ããé«ãçºççã«è²¢ç®ããŠããŸã æ³å®äºäŸ ç·©åã±ã¢ããã³æ¹åããã質ã®ã... ãã£ãšèŠã
èè±çæ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2026 - 2033幎äžçã®Blepharitisã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯ã§ãããšæšå®ãããŸã 2026幎ã®USD 1.3åã§è©äŸ¡ãããUSD 2.1ã«éããèŠèŸŒã¿ 2033幎10æãååç©ã®å¹Žéæé·ç(CAGR)ã7.2%å¢ 2026幎ïœ2033幎ãããã£ãŒã«èè±çã®åŠçœ®ã®åžå Žã¯äžæã®åvalenceã«ãã£ãŠé転ãããŸã æ ¢æ§çŒé害ããã©ã€ã¢ã€çå矀ã®çºççã®å¢å ãããã³ çŒçŒè¡çããã³çŒç§ã®å¥åº·ã®é«ããããæèã ãšã€ãžã³ã° èè±çãé¢é£çŒã«ææãªäººå£ æ¡ä»¶ã¯ãåžå Žæé·ãæ¯ããŸãã 蚺æã®é²æ© æšççæ³ã®æè¡ãããŠéçºããå«ã åŠæ¹è¬ããµãã¯ã¹ã¯ã©ããããã³å ... ãã£ãšèŠã
å»ç廿£ç©ç®¡ç åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎ã°ããŒãã«å»ç廿£ç©ç®¡ç åžå ŽèŠæš¡ã¯æšå®ããã 2026幎ã®USD 15.8åã§è©äŸ¡ãããUSD 27.3ã«éããèŠèŸŒã¿ 2033幎(æå40幎)ã«å¢æ®ç(CAGR)ã8.4%å¢ 2026幎ïœ2033幎ãããã£ãŒã«å»ç廿£ç©ç®¡çåžå Žã¯å¢å ã«ãã£ãŠé転ãããŸã ç é¢ã®å ¥é¢ã«äŒŽããã«ã¹ã±ã¢å»æ£ç©ã®çºç äžçåå°ã®å»çã€ã³ãã©ã®æŽåãšæ®å ææç®¡çãšå³ããæ¿åºã®æèã®æ¡å€§ çç©å»åŠå»æ£ç©ã®å®å šãªåŠåã®ããã®èŠåã¯éèŠãªèŠå ã§ã æ¯æã®èŠæ±ã ææãšæ ¢æ§ã®èå»¶ã«äžæ çŸæ£ã¯ãé©åãªå»æ£ç©åŠçã®å¿ èŠæ§ãããã«åŒ·åããŸãã æ±æããã³ç°å¢ã®å±éºã... ãã£ãšèŠã
ãªã¡ãã©ãŸãŒã«ã®äžçåžå Ž - é žå³ã®ç®¡ç ãªã¡ãã©ãŸãŒã«ã¯ãäžè¬çã«åŠæ¹ããããããã³ãã³ãé»å®³è¬ïŒPPIïŒã§ãããèé žãæžå°ãããããªã¡ãã©ãŸãŒã«ã¯ãèé£ééæµçïŒGERDïŒã«äŒŽãèžããããã®ä»ã®çç¶ã®æ²»çè¬ãšããŠèŠå¶åœå±ããæ¿èªãããŠããããªã¡ãã©ãŸãŒã«ã¯ãã³ããæ§é£éçïŒèé žã«ããé£éæå·ïŒã®æ²»çä¿é²ã«ã䜿çšãããã ãªã¡ãã©ãŸãŒã«ã¯ãã¢ã¢ãã·ã·ãªã³ãã¯ã©ãªã¹ããã€ã·ã³ãªã©ã®æçç©è³ªãšçµã¿åãããŠããããªèã«ããæœ°çã®æ²»çã«äœ¿çšãããã ãªã¡ãã©ãŸãŒã«ã®äžçåžå ŽèŠæš¡ã¯2017幎ã«26å6,840äžç±³ãã«ãšè©äŸ¡ãããäºæž¬æéïŒ2018幎ïœ2026幎ïŒã®CAGRã¯5.2%ãšäºæ³ãããŠ... ãã£ãšèŠã
å¯çè«ã¯ã¬ã³ãºåžå Žã補åã¿ã€ãå¥ïŒããŒãå¯çè«ã¯ã¬ã³ãºè£œåãå»è¬åæå¯çè«è£œåãæ é€è£å©é£åããããã¯ã¹ããã³é å補å€ïŒãã¢ããªã±ãŒã·ã§ã³å¥ïŒè žå å¯çè«ç®¡çãæ¶ååšã®å¥åº·ãµããŒããäžè¬çãªãŠã§ã«ãã¹ããã³äºé²ã±ã¢ãããã³ç£å»çšéïŒãæµéãã£ãã«å¥ïŒè¬å±ããã³ãã©ãã°ã¹ãã¢ãã¹ãŒããŒããŒã±ããããã³ãã€ããŒããŒã±ãããå°éå¥åº·åºãããã³ãªã³ã©ã€ã³å°å£²ïŒãå°çå¥ (åç±³ãã©ãã³ã¢ã¡ãªã«ããšãŒããããã¢ãžã¢å€ªå¹³æŽãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
æµ·æŽãªã¡ã¬3åžå ŽããœãŒã¹å¥ïŒéæ²¹ããªãã¢ãæ²¹ãè»é¡æµ·æŽæ²¹ãªã©ïŒã圢æ å¥ïŒããªã°ãªã»ãªãããšãã«ãšã¹ãã«ããªã³è質ãªã©ïŒãçšéå¥ïŒæ é€è£å©é£åãå»è¬åãæ©èœæ§é£åããã³é£²æãä¹³å çšæ é€ãåç©æ é€ïŒãæµéãã£ãã«å¥ïŒè¬å±ããã³ãã©ãã°ã¹ãã¢ãã¹ãŒããŒããŒã±ããããã³ãã€ããŒããŒã±ãããå°éåºã ãªã³ã©ã€ã³å°å£²)ãå°çå¥ (åç±³ãã©ãã³ã¢ã¡ãªã«ããšãŒããããã¢ãžã¢å€ªå¹³æŽãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
å°å èåŸ ã®ç²Ÿç¥çæ²»çåžå Ž - æŽå¯åŠåš äžã®çºäœ(äž»ã«ãã-malãšããŠç¥ããã)ã¯ãæäººãããé »ç¹ã«èµ·ãããšããèŠãããŸãã 4æ³ãã7æ³ãŸã§ã®å°å æ¬ ä¹ã®çºäœãå§ãŸããŸãã 幎霢ã4æ³ãã8æ³ã«ãªããŸã§ã¯ããŸããŸããã äžæ¥äž10ïœ100åããã¯ãã¬ãã·ãŒãšããŠç¥ããããã»ã€ãŸã¬ã¹ãã¯ãæ°åçºçããŸãã ã»ã€ãŸã¬ã¹ã¯ãçºäœã®æ§è³ªã«å¿ããŠãå žåçã§å žåçãªæ¬ åŠã®çºäœç©ã«åããããŸãã ããã€ãã®ä»ã®ç æ°ã®çç¶ã¯ããã€ç ã«äŒŒãŠããããã«ããã€ç ã蚺æããããšã¯å°é£ã§ããããšã蚌æããŸãã äžéšã®ãããã³ã«ã¯ãçºäœã®çºçæ¥ãæéãããã³ããç°¡åãªèšºæã®ããã®è©³çްãªèª¬æã®æ¥èšãç¶æãããªã©ã®æ£è ã«åŸã... ãã£ãšèŠã